Trial · NCT00734032
Results by group32
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 32
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to Week 4 in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity | Placebo | 0.961 | Geometric Coefficient of Variation 8.5 | Log(millimole per milliliter per minute) | |
| Change From Baseline to Week 4 in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity | SB-480848 40 mg | 0.494 | Geometric Coefficient of Variation 24.6 | Log(millimole per milliliter per minute) | |
| Change From Baseline to Week 4 in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity | SB-480848 80 mg | 0.404 | Geometric Coefficient of Variation 21.5 | Log(millimole per milliliter per minute) | |
| Change From Baseline to Week 4 in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity | SB-480848 160 mg | 0.313 | Geometric Coefficient of Variation 24.7 | Log(millimole per milliliter per minute) | |
| Percent Inhibition of Lp-PLA2 Activity in Plasma Over Time | Placebo | Week 1 | -4.06 | Standard Deviation 7.025 | Percent inhibiton of Lp-PLA2 activity |
| Percent Inhibition of Lp-PLA2 Activity in Plasma Over Time | SB-480848 40 mg | Week 1 | -48.25 | Standard Deviation 15.929 | Percent inhibiton of Lp-PLA2 activity |
| Percent Inhibition of Lp-PLA2 Activity in Plasma Over Time | SB-480848 80 mg | Week 1 | -55.83 | Standard Deviation 11.031 | Percent inhibiton of Lp-PLA2 activity |
| Percent Inhibition of Lp-PLA2 Activity in Plasma Over Time | SB-480848 160 mg | Week 1 | -66.03 | Standard Deviation 7.656 | Percent inhibiton of Lp-PLA2 activity |
| Percent Inhibition of Lp-PLA2 Activity in Plasma Over Time | Placebo | Week 2 | -1.96 | Standard Deviation 8.147 | Percent inhibiton of Lp-PLA2 activity |
| Percent Inhibition of Lp-PLA2 Activity in Plasma Over Time | SB-480848 40 mg | Week 2 | -49.05 | Standard Deviation 11.094 | Percent inhibiton of Lp-PLA2 activity |
| Percent Inhibition of Lp-PLA2 Activity in Plasma Over Time | SB-480848 80 mg | Week 2 | -58.95 | Standard Deviation 8.258 | Percent inhibiton of Lp-PLA2 activity |
| Percent Inhibition of Lp-PLA2 Activity in Plasma Over Time | SB-480848 160 mg | Week 2 | -67.52 | Standard Deviation 9.402 | Percent inhibiton of Lp-PLA2 activity |
| Percent Inhibition of Lp-PLA2 Activity in Plasma Over Time | Placebo | Week 4 | -3.59 | Standard Deviation 7.822 | Percent inhibiton of Lp-PLA2 activity |
| Percent Inhibition of Lp-PLA2 Activity in Plasma Over Time | SB-480848 40 mg | Week 4 | -49.05 | Standard Deviation 13.472 | Percent inhibiton of Lp-PLA2 activity |
| Percent Inhibition of Lp-PLA2 Activity in Plasma Over Time | SB-480848 80 mg | Week 4 | -58.67 | Standard Deviation 9.438 | Percent inhibiton of Lp-PLA2 activity |
| Percent Inhibition of Lp-PLA2 Activity in Plasma Over Time | SB-480848 160 mg | Week 4 | -67.73 | Standard Deviation 8.310 | Percent inhibiton of Lp-PLA2 activity |
| Percent Inhibition of Lp-PLA2 Activity in Plasma Over Time | Placebo | Week 7 (Follow-up) | -3.16 | Standard Deviation 9.018 | Percent inhibiton of Lp-PLA2 activity |
| Percent Inhibition of Lp-PLA2 Activity in Plasma Over Time | SB-480848 40 mg | Week 7 (Follow-up) | -7.65 | Standard Deviation 11.408 | Percent inhibiton of Lp-PLA2 activity |
| Percent Inhibition of Lp-PLA2 Activity in Plasma Over Time | SB-480848 80 mg | Week 7 (Follow-up) | -9.40 | Standard Deviation 8.667 | Percent inhibiton of Lp-PLA2 activity |
| Percent Inhibition of Lp-PLA2 Activity in Plasma Over Time | SB-480848 160 mg | Week 7 (Follow-up) | -13.36 | Standard Deviation 10.244 | Percent inhibiton of Lp-PLA2 activity |
Source ClinicalTrials.govtrials-2026-11-12-0.4.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00734032/results